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OBJECTIVES To describe from a population-based perspective, recent and temporal (1975–1995) trends in
the incidence, in-hospital and postdischarge case-fatality rates of heart failure (HF)
complicating acute myocardial infarction (AMI).
BACKGROUND Extremely limited data are available describing the incidence and case-fatality rates associated
with HF complicating AMI from a community-wide perspective.
METHODS The medical records of 6,798 residents of the Worcester, Massachusetts metropolitan area
with validated MI and without previous HF hospitalized in 10 annual periods between 1975
and 1995 were reviewed.
RESULTS The proportion of AMI patients developing HF during hospitalization declined between
1975–1978 (38%) and 1993–1995 (33%) (p , 0.001). After controlling for potentially
confounding factors, the risk of developing HF declined progressively, albeit modestly, over
time. In-hospital case-fatality rates of patients with AMI complicated by HF declined by
approximately 46% between 1975–1978 (33%) and 1993–1995 (18%) (p , 0.001). Improving
trends in hospital survival were observed after adjusting for potentially confounding
prognostic factors. The one-year post-discharge mortality rate for hospital survivors of HF
did not change over the 20-year period under study, even after controlling for additional
prognostic characteristics.
CONCLUSIONS The results of this community-wide study suggest encouraging declines in the incidence and
hospital death rates associated with HF complicating AMI. Continued efforts need to be
directed towards the prevention of HF given the magnitude of this clinical syndrome. Efforts
of secondary prevention are needed to identify and improve the treatment of patients with
symptomatic left ventricular dysfunction following AMI given the lack of improvement in the
long-term prognosis of these patients. (J Am Coll Cardiol 1999;34:1378–87) © 1999 by the
American College of Cardiology
Heart failure (HF) occurring as an acute complication of
myocardial infarction (MI) is relatively prevalent and is
associated with increased short-term mortality. More than
30 years ago, Killip recognized the importance of prognos-
ticating patients with acute myocardial infarction (AMI)
according to increasing hemodynamic instability (1). Sub-
sequently, a number of studies identified clinical signs of left
ventricular failure during and immediately after AMI as
important predictors of prognosis (2–7). The relatively
recent and widespread availability of improved cardiac
imaging techniques have allowed for more direct estimates
of infarct size and left ventricular function. The increased
use of these techniques may have contributed to a decreased
emphasis of the prognostic importance of the clinical
syndrome of HF in the setting of AMI. Recent advances in
therapeutic interventions for both AMI and HF may have
resulted in declines in the incidence and mortality rates of
HF following AMI though limited data are available to
support this claim. On the other hand, it is generally
accepted that older patients with more comorbidities are
being treated for AMI and HF which could, in turn,
increase these rates. Due to changing patient demographic
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and clinical characteristics and development and application
of improved therapeutic interventions for AMI, it is also
uncertain whether HF complicating AMI carries the same
clinical and prognostic significance it once did more than
three decades ago. Virtually no data are available to describe
recent and temporal trends in the incidence and mortality
rates associated with HF complicating AMI, particularly
from a community-wide perspective.
The purpose of this population-based study was to
determine whether the incidence and clinical impact of HF
complicating AMI has changed over a 20-year period of
study (1975–1995). Data obtained from community-wide
studies may be more generalizable to a broader spectrum of
patients with HF and provide a more representative picture
of the natural history of this clinical syndrome than data
derived in the context of clinical trials in more restricted
patient samples. In addition, given the encouraging results
of recent randomized trials in the medical management of
patients with HF, temporal trends in the treatment of
patients with HF complicating AMI are presented.
MATERIALS AND METHODS
Residents of the Worcester, Massachusetts metropolitan
area hospitalized with a primary or secondary discharge
diagnosis of AMI [International Classification of Disease
(ICD-9) code 410] from all 16 Worcester standard metro-
politan statistical area (SMSA) hospitals during 1975, 1978,
1981, 1984, 1986, 1988, 1990, 1991, 1993 and 1995
comprised the study population. In addition, a random
sample of records from related diagnostic rubrics in which
the diagnosis of AMI might have occurred (e.g., ICD codes
411 and 412) was carried out during each of the years under
study to identify potentially misclassified cases of AMI. All
hospitals in the Worcester SMSA (1990 census popula-
tion 5 437,000) participated in this study. Fewer hospitals
were included in recent years due to hospital closures,
mergers, or conversion to chronic care facilities. The med-
ical records of Worcester SMSA residents with a discharge
diagnosis of AMI from these hospitals were individually
reviewed and validated according to preestablished diagnos-
tic criteria that have been previously described (8–10). In
brief, these criteria included a clinical history of prolonged
chest pain not relieved by rest or use of nitrates, serum
enzyme level elevations in excess of the upper limit of
normal as specified by the laboratory at each hospital, and
serial electrocardiographic tracings during hospitalization
showing changes in the ST segment or Q-waves typical of
AMI. At least two of these three criteria needed to be
satisfied for study inclusion. All autopsy-proven cases of
AMI were included irrespective of the other criteria. Cases
of perioperative associated AMI were not included.
For the periods under study, the complications of AMI
were assessed on the basis of information available from
clinical charts (11,12). Heart failure was regarded as present
when there was clinical or radiographic evidence of pulmo-
nary edema or bilateral basilar rales with an S3 gallop.
This report is based on information about the 6,798
residents of the Worcester metropolitan area who satisfied
the diagnostic criteria for AMI in the ten one-year periods
examined and who did not have a history of HF. These ten
study periods were aggregated into five periods for purposes
of analysis as well as to coincide with changes in the medical
management of patients with AMI. Among the study
sample, 1,402 patients were hospitalized in 1975–1978,
1,439 in 1981–1984, 1,231 in 1986–1988, 1,259 in 1990–
1991 and 1,467 in 1993–1995.
Data collection. The hospital records of patients with
validated AMI were abstracted for demographic and clinical
data including age, gender, clinical complications during
hospitalization, MI order (initial or recurrent), MI type
(Q-wave or non–Q-wave) and MI location (anterior or
inferior/posterior). The approaches used to ascertain sur-
vival status after hospital discharge included a review of
records for additional hospitalizations and a statewide and
national search of death certificates. Some form of addi-
tional follow-up was ascertained for the vast majority (99%)
of residents of the Worcester SMSA discharged from
area-wide hospitals following AMI.
Data analysis. Differences in the distributions of demo-
graphic and clinical characteristics between patients with
AMI according to the development of HF during the acute
hospitalization were examined by using chi-square tests of
statistical significance. The short-term prognosis in each
period was examined by calculating in-hospital case-fatality
rates (CFRs). The simultaneous effect of several potentially
confounding variables that might influence the development
of HF during the acute hospitalization, as well as in-hospital
death rates associated with HF, was accounted for by means
of a logistic multiple regression technique. Because of the
observational, nonrandomized nature of this study, and
because of our methods of data collection which did not
allow us to determine whether a medical therapy or surgical
intervention preceded or came after the occurrence of HF,
we did not control for the use of coronary interventional
procedures or medical therapies. Another reason we did not
control for these practices is the difficulty of interpreting any
observed adjusted estimates of association. Our approach to
model building focused on the hypothesis that variations in
the incidence of HF over time were the result of changes in
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass grafting
CFR 5 case-fatality rate
CI 5 confidence interval
HF 5 heart failure
MI 5 myocardial infarction
SMSA 5 standard metropolitan statistical area
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the demographic or clinical characteristics (or both) of the
study sample. We recognize that these trends might also
reflect improvements in the use of various approaches to
care, and increasing use of these approaches, over the
20-year period under study. Logistic regression analysis was
also used to examine time trends in one-year post-hospital
discharge mortality according to the development of HF
during the acute hospitalization while adjusting for the
effect of several potentially confounding prognostic vari-
ables.
RESULTS
Characteristics of patients with HF complicating AMI.
Patients with AMI who developed HF during hospitaliza-
tion were older, were more likely to be female and were
significantly more likely to have a history of angina, hyper-
tension, stroke or diabetes as compared with AMI patients
who did not develop HF. Their presentation was also more
commonly a recurrent, anterior and Q-wave MI compared
with those not developing HF (Table 1).
As might be expected, over the two decades under study,
patients developing HF were increasingly older and sicker.
The mean age of patients with HF increased by four years
over the 20-year study period and patients developing HF
during more recent periods were more likely to include
those with a history of hypertension, stroke or diabetes.
On the other hand, patients developing HF less frequently
presented with an anterior or Q-wave MI over time
(Table 2).
Management practices and temporal trends therein.
Over the 20-year study period, medication use differed
according to whether or not HF was present. Patients with
HF were significantly more likely to have angiotensin
converting enzyme (ACE) inhibitors and digoxin either
maintained or initiated during the acute hospitalization as
compared with patients without HF (Table 3). Patients
with HF were also much more likely to be discharged on
these therapies. Antiplatelet agents, beta-adrenergic block-
ing agents and calcium channel blockers were used less
frequently in patients with MI complicated by HF as
compared with those not developing HF during the acute
hospitalization.
Table 1. Characteristics of Patients With AMI According to
Occurrence of Heart Failure: Worcester Heart Attack Study
Characteristic
HF Present
(n 5 2,558)
HF Absent
(n 5 4,240)
p
Value
Age (yrs)
,55 10.4 24.0
55–64 19.0 26.7
65–74 31.0 27.2 , 0.001
$75 39.6 22.0
Mean age (yrs) 70.4 63.9 , 0.001
Male 55.8 67.0 , 0.001
Medical history
Angina (1) 27.8 22.6 , 0.001
Hypertension (1) 53.0 46.7 , 0.001
Stroke (1) 10.6 5.5 , 0.001
Diabetes (1) 27.4 18.7 , 0.001
AMI characteristics
Initial 64.6 75.0 , 0.001
Anterior 54.6 40.7 , 0.001
Q-wave 59.4 53.8 , 0.001
AMI 5 acute myocardial infarction; HF 5 heart failure.
Table 2. Temporal Trends in the Characteristics of Patients With AMI Developing Heart Failure: Worcester Heart Attack Study
Characteristic
Time Period
1975/78
(n 5 537)
1981/84
(n 5 627)
1986/88
(n 5 461)
1990/91
(n 5 448)
1993/95
(n 5 485)
p
Value
Age (yrs) (%)
,55 14.3 10.5 7.2 10.0 9.1
55–64 22.9 21.4 17.8 17.0 14.4
65–74 30.4 31.9 32.8 29.9 30.1 , 0.001
$75 32.4 36.2 42.3 43.1 46.4
Mean age (yrs) 67.9 69.8 71.7 71.1 72.1 , 0.001
Male (%) 57.0 60.0 52.3 53.4 54.4 0.075
Medical history (%)
Angina 24.8 31.3 27.6 27.2 27.4 0.18
Hypertension 43.8 52.5 53.6 56.3 60.4 , 0.001
Stroke 6.5 8.5 12.6 12.5 14.0 , 0.001
Diabetes 25.0 24.4 28.0 28.8 32.4 0.03
AMI characteristics (%)
Initial 65.9 62.5 67.7 65.6 61.9 0.26
Anterior 55.7 60.5 59.2 49.6 46.4 , 0.001
Q-wave 77.7 64.5 54.1 51.8 45.8 ,0.001
AMI 5 acute myocardial infarction.
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There were marked changes over time in the use of
certain medications (Fig. 1) and coronary revascularization
procedures (Fig. 2) in the study sample. The use of
beta-blockers increased steadily over time in patients with
and without HF, though utilization rates remained lower in
the HF group overall as well as during each period under
study. The use of antiplatelet agents increased in patients
with and without HF. Use of digoxin also increased over
time with use being nearly 3–4 times greater in patients
with as compared with those without HF. Angiotensin
converting enzyme inhibitors were used in an approximately
similar ratio in patients with as compared with those
without HF during 1993–1995. In the two most recent
study years, approximately 27% of patients developing
post-MI HF received thrombolytics compared with 31% of
patients without HF.
Cardiac catheterization was performed more frequently in
patients without HF though by the most recent study period
these rates were relatively comparable in patients with (41%)
and without HF (39%). Rates of coronary artery bypass
grafting (CABG) remained low in both groups reaching
highs of 7% in the HF group and 4% in the non-HF group
in 1993–1995. Coronary angioplasty was used in approxi-
mately 15% of AMI patients, irrespective of occurrence of
HF, in 1993–1995.
Incidence rates of HF complicating AMI. Heart failure
developed in approximately 38% of patients with validated
AMI over the 20-year study period. As noted previously, we
aggregated the ten individual study years into five periods to
make trends in the proportion of AMI patients developing
HF more interpretable as well as to coincide with changes in
the management of patients with AMI. A decline in the
crude unadjusted incidence rate of HF was noted between
1975–1978 and 1993–1995 though increases in these rates
were noted during the initial study years (Table 4).
Given changes in patient demographic, medical history
and clinical characteristics over the two decades of this
study, we examined trends in the risk of developing HF
after adjusting for age, gender, comorbid conditions (history
of angina, diabetes, hypertension or stroke) and AMI
associated characteristics (Table 4). After adjusting for age
and gender only, the odds of developing HF decreased
progressively and significantly over time with the lowest
observed risk seen during the most recent period of hospi-
talization. In 1993–1995, AMI patients were at approxi-
mately one-third lower risk for developing HF than patients
hospitalized with AMI in 1975–1978. The multivariable
adjusted odds of developing HF also declined over the
20-year study period though the decrease in risk was
attenuated after controlling for additional comorbidities and
AMI associated characteristics.
In-hospital case-fatality rates. The in-hospital case-
fatality rate for patients with HF declined significantly over
time from 32.6% during 1975–1978 to 17.7% in 1993–1995
(p , 0.001). The short-term case fatality rates for AMI
patients without HF remained relatively stable at approxi-
mately 7% to 9% for this period (Fig. 3).
The age, gender and multivariable adjusted odds of dying
following HF declined progressively over time (Table 5).
Compared with patients hospitalized approximately 20
years earlier, the risk of dying following the development of
HF declined by approximately 60% depending on the
covariates adjusted for with particularly marked declines in
hospital mortality observed during the 1990s. Despite these
Table 3. Use of Therapies in Patients With Acute Myocardial Infarction According to
Occurrence of Heart Failure: Worcester Heart Attack Study
HF Present
(n 5 2,558)
HF Absent
(n 5 4,240)
p
Value
Therapies Maintained or Initiated During Acute Hospitalization (%)
ACE inhibitors* 42.8 13.4 , 0.001
Antiplatelet agents 36.7 47.6 , 0.001
Beta21 blockers 37.7 55.5 , 0.001
CA blockers† 46.3 48.2 0.28
Digoxin 37.3 11.7 , 0.001
Thrombolytics† 21.2 27.6 , 0.001
Discharge Medications (%)
ACE inhibitors* 28.5 9.3 , 0.001
Antiplatelet agents 24.0 36.8 , 0.001
Beta blockers 25.0 47.5 , 0.001
CA21 blockers† 27.0 36.1 , 0.001
Digoxin 28.0 8.8 , 0.001
Procedures (%)
Cardiac catheterization 18.0 20.7 , 0.01
CABG 2.3 1.9 0.28
PTCA† 6.8 8.6 , 0.04
*Data available for the period 1990–1995; †Data available for the period 1986–1995.
HF 5 heart failure.
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impressive declines in hospital death rates, patients with HF
remained at significantly greater risk for dying than patients
without HF. Over the entire study, the multivariable ad-
justed odds of dying from HF (as compared with those
without HF) was 2.71 (95% confidence interval [CI] 5
2.31, 3.18).
We carried out an additional analyses in which the
characteristics of patients with HF who survived the acute
hospitalization were compared with those who died, overall
as well as during the most recent study years (Table 6).
Patients developing HF during the mid-1990s were specif-
ically studied to determine whether or not the profile of
patients dying from HF had changed during recent years.
Patients surviving HF were significantly younger, less
likely to have a history of stroke, more likely to experience
an inferior/posterior, non–Q-wave AMI and were more
likely to be treated with each of the medications under
study. Similar findings were observed in contrasting the
characteristics of hospital survivors of HF in 1993–1995 as
compared with those who did not survive the acute hospi-
talization. While an increasingly greater proportion of
patients developing HF were treated with each of the
therapies examined during the mid 1990s, with the excep-
tion of calcium channel blockers whose overall use declined,
patients surviving HF in the mid 1990s were significantly
more likely to be treated with ACE inhibitors, antiplatelet
Figure 1. (A) Trends in the use of cardiac medications maintained or initiated during hospitalization according to presence of heart failure
(HF) complicating acute myocardial infarction: Worcester Heart Attack Study. (B) Trends in the use of cardiac medications at the time
of hospital discharge according to presence of HF complicating acute myocardial infarction: Worcester Heart Attack Study.
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agents, beta-blockers and thrombolytic therapy than HF
patients who did not survive the acute hospitalization.
Long-term survival. Given declining hospital death rates
among patients with HF, we examined trends in post-
discharge survival associated with HF occurring during the
acute hospitalization to determine whether or not survival
patterns following hospital discharge had similarly im-
proved. For this analysis, we examined the risk of dying
during the first year following hospital discharge given the
marked increase in death rates during this period and the
abbreviated long-term follow-up available for those hospi-
talized in the most recent cohort. The cumulative one-year
mortality for patients with AMI complicated by HF did not
change over time (Fig. 4). The one-year mortality rates were
20.7% for patients discharged in 1975–1978, 21.3% for
those discharged in 1986–1988 and 21.1% for those dis-
charged in 1993–1995.
Since the demographic, medical history and clinical charac-
teristics of patients discharged from area-wide hospitals fol-
lowing AMI may have changed over time, we examined trends
in one-year death rates among patients with HF while con-
trolling for these covariates. After adjusting for age and gender
only, compared with patients discharged in 1975–1978, the
adjusted odds of dying within the first year following hospital
discharge for HF were 1.33 (95% CI 5 0.96, 1.86) in
1981–1984, 0.85 (95% CI 5 0.59, 1.24) in 1986–1988, 1.06
(95% CI 5 0.74, 1.52) in 1990–1991 and 0.80 (95% CI 5
0.56, 1.15) for patients discharged in 1993–1995. After con-
trolling for these demographic characteristics plus previously
described medical history and clinical characteristics, the mul-
tivariable adjusted odds of dying during the first year following
hospital discharge also exhibited inconsistent trends over time.
These adjusted risks of dying were 1.28 (95% CI 5 0.90, 1.83)
in 1981–1984, 0.81 (95% CI 5 0.54, 1.21) in 1986–1988, 1.05
(95% CI 5 0.72, 1.53) in 1990–1991 and 0.76 (95% CI 5
0.52, 1.12) in 1993–1995 in comparison with patients dis-
charged in 1975–1978.
Figure 2. Trends in the use of coronary revascularization
procedures according to presence of heart failure (HF) com-
plicating acute myocardial infarction: Worcester Heart Attack
Study.
Figure 3. Trends in hospital case fatality rates (CFR) according to
the presence of heart failure (HF) complicating acute myocardial
infarction: Worcester Heart Attack Study.
Table 4. Time Trends in the Multivariable Adjusted Odds of Developing Heart Failure in
Patients With AMI: Worcester Heart Attack Study
Time Period % Developing HF
Crude
Odds Ratio
Adjusted for Age
and Gender
Multivariable
Adjusted Odds
Ratio*
1975/78 38.3 1.0 1.0 1.0
1981/84 43.6 1.24
(1.07, 1.45)†
1.15
(0.99, 1.35)
1.20
(1.02, 1.41)
1986/88 37.5 0.96
(0.82, 1.13)
0.86
(0.73, 1.01)
0.92
(0.77, 1.09)
1990/91 35.6 0.89
(0.76, 1.04)
0.76
(0.65, 0.90)
0.89
(0.75, 1.05)
1993/95 33.1 0.80
(0.68, 0.93)
0.67
(0.57, 0.78)
0.81
(0.69, 0.96)
*Adjusted for age, gender, comorbid conditions, AMI order, AMI type and AMI location. †95% CI.
AMI 5 acute myocardial infarction; CI 5 confidence interval; HF 5 heart failure.
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DISCUSSION
The results of the present analysis from the Worcester
Heart Attack Study suggest encouraging declines in the
incidence rates of HF complicating AMI and significant
improvements in hospital survival following AMI compli-
cated by HF. Inconsistent and nonsignificant trends in
post-discharge survival were seen among patients dis-
charged from greater Worcester hospitals following HF
during the most recent study years.
Incidence rates of HF. There is a paucity of studies that
have described the incidence rates of HF complicating AMI
and limited data are available describing temporal trends in
the risk of developing HF in the setting of AMI. Separate
studies of hospitalized patients with AMI conducted from
Table 5. Time Trends in the Multivariate Adjusted Odds of Dying in Hospital Following Heart
Failure Complicating AMI: Worcester Heart Attack Study
Time Period % Dying
Crude Odds
Ratio
Adjusted for Age
and Gender
Multivariable
Adjusted
Odds
Ratio*
1975/78 32.6 1.0 1.0 1.0
1981/84 26.0 0.73
(0.56, 0.94)†
0.66
(0.51, 0.86)
0.73
(0.55, 0.96)
1986/88 27.8 0.80
(0.61, 1.04)
0.68
(0.51, 0.89)
0.80
(0.59, 1.08)
1990/91 19.9 0.51
(0.38, 0.69)
0.43
(0.32, 0.59)
0.52
(0.38, 0.71)
1993/95 17.7 0.45
(0.33, 0.60)
0.36
(0.27, 0.49)
0.46
(0.33, 0.63)
*Adjusted for age, gender, comorbid conditions, AMI order, AMI type and AMI location. †95% CI.
AMI 5 acute myocardial infarction; CI 5 confidence interval.
Table 6. Characteristics of Patients With AMI Complicated by Heart Failure Surviving and Not Surviving the Acute Hospitalization:
Worcester Heart Attack Study
Characteristic
Total Sample 1993/95 Cohort
Survived
(n 5 1,917)
Died
(n 5 641)
p
Value
Survived
(n 5 399)
Died
(n 5 86)
p
Value
Age (yrs)
,55 12.4 4.4 10.3 3.5
55–64 20.5 14.5 , 0.001 15.8 8.1 , 0.001
65–74 32.0 28.1 30.0 30.2
$75 35.2 53.0 43.9 58.1
Male 56.8 52.6 0.06 55.4 50.0 0.36
Medical History
Angina 27.9 27.6 0.91 28.3 23.3 0.34
Hypertension 54.0 50.1 0.09 60.2 61.6 0.80
Stroke 9.8 12.8 , 0.05 12.5 20.9 , 0.05
Diabetes 28.1 25.6 0.22 33.3 27.9 0.33
AMI Characteristics
Initial 65.2 62.9 0.30 62.4 59.3 0.59
Anterior 53.0 59.1 , 0.01 46.4 46.5 0.98
Q-wave 55.5 71.2 , 0.001 43.1 58.1 , 0.025
Therapy*
ACE inhibitors 44.7 34.3 , 0.025 51.6 39.5 , 0.05
Antiplatelets 42.5 19.5 , 0.001 93.0 81.4 , 0.001
Beta blockers 44.6 17.0 , 0.001 75.9 41.9 , 0.001
CA21 blockers 48.8 37.6 , 0.001 37.3 26.7 0.06
Digoxin 41.8 23.9 , 0.001 45.1 43.0 0.72
Thrombolytics 23.3 13.5 , 0.001 29.3 18.6 , 0.05
*Maintained or initiated during hospitalization.
AMI 5 acute myocardial infarction.
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1979 to 1981, 1974 to 1984 and 1986 to 1987 identified HF
in 48%, 41% and 51% of patients respectively (7,13,14). A
more recent trial, the Acute Infarction Ramipril Efficacy
Study, screened nearly 31,000 patients with AMI from 144
participating trial centers over the period 1989–1992; 45%
of study patients had evidence of HF (15). While the results
of these different studies in varying patient samples suggest
no improvement over time in the incidence rates of HF
complicating AMI, extrapolation of these results to a
community-based sample of patients with HF is tenuous
and fraught with difficulties in interpretation. This is be-
cause of differences in the characteristics of the study
populations, working definitions of HF and AMI and
treatment approaches that were used which may have
affected the risk of developing HF.
Reasons for the declining incidence rates of HF observed
in the present population-based study are not readily appar-
ent. While patients developing HF over the 20-year study
period were older and were more likely to have serious
comorbid conditions present, the proportion of AMI pa-
tients experiencing HF nonetheless declined, with these
declines being most marked during the 1990s. While it is
possible that trends in the incidence rates of HF may reflect
changes in patient clinical characteristics, such as a declining
proportion of patients with Q-wave infarcts, control for
these and additional potentially confounding variables was
carried out to analytically adjust for these changing patient
characteristics over the 20-year study period. Changes over
time in the incidence as well as death rates associated with
HF may also reflect inadequate measurement of, or failure
to measure, additional covariates that might affect the risk of
developing, or dying from, HF. These encouraging trends
likely reflect the increasing use of preventive and aggressive
therapeutic strategies directed at patients at high risk for
developing HF with the end result of declining incidence.
Hospital death rates associated with HF. Declines in the
unadjusted hospital case-fatality rates for AMI patients
developing HF were observed between 1975 and 1995.
These declines became even more pronounced after multi-
variable adjustment for additional prognostic confounders,
including the advancing age of study patients and presence
of comorbid conditions. Relatively little change was ob-
served in the hospital death rates of AMI patients who did
not develop HF.
Over the last two decades numerous studies, especially
those assessing the efficacy of coronary reperfusion ap-
proaches, have documented steadily decreasing hospital
death rates following AMI (16–19). However, none of
these studies specifically examined changes over time in
hospital mortality associated with HF complicating AMI.
To the best of our knowledge, this is the first community-
based study that has examined changes over time in hospital
mortality associated with HF, documenting a consistent
decline in short-term mortality in patients with this clinical
syndrome. In previous publications from the Worcester
Heart Attack Study we have demonstrated declining hos-
pital death rates associated with AMI (10,20), including an
earlier report from this study that examined trends in
hospital mortality in patients with HF (21). It is important
to note, however, that the development of HF as recently as
1993–1995 was still associated with an increased risk of
dying in comparison with those not suffering HF. As such,
a diagnosis of HF in the setting of AMI retains its
importance as a prognostic indicator of a poor outcome.
Furthermore, the present results suggest that deaths
among patients with HF may be preventable, or at least
postponed, as subgroups at increased risk for dying follow-
ing HF were identified. In particular, the elderly, patients
with a history of stroke and those with a more extensive
AMI were more likely to die from HF than respective
comparison groups. In addition, patients dying after HF
were significantly less likely to be treated with agents shown
to be effective in the management of AMI. While we did
not adjust our study findings for the increasing use of
effective cardiac therapies (given the nonrandomized nature
of the present study), these data provide encouragement for
the increasing effectiveness of modalities designed to reduce
infarct size, prevent recurrent myocardial ischemia and
favorably alter left ventricular remodeling. Our results sug-
gest that further intervention efforts should be directed to
these high risk patients with the goals of improving survival
in patients with HF following AMI.
Long-term survival following HF. Few studies have de-
scribed mortality following hospital discharge for patients
with HF complicating AMI. In addition, we were unable to
identify any studies describing temporal trends in long-term
mortality among AMI patients developing HF. A small
study of 39 survivors of AMI with pulmonary edema
conducted in 1981 documented a 29% mortality rate over
the ensuing nine months (22). In a study of 440 AMI
patients with HF seen at a single hospital from 1986–1987,
the one-year mortality was 39% (14). Analysis of screening
Figure 4. Trends in one-year case-fatality rates of discharged
hospital patients according to presence of heart failure (HF)
complicating acute myocardial infarction: Worcester Heart Attack
Study.
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data from the Trandalopril Cardiac Evaluation Study
(1990–1992) revealed an approximate 43% one-year mor-
tality in AMI patients with HF (23). When assessed
chronologically, despite the caveats involved in extrapolat-
ing from different studies carried out in different settings
and study samples, these studies fail to reveal any patterns of
improvement in the one-year mortality rates of this high
risk subset of patients.
These trends are in agreement with the findings of this
study in which no discernible trends in one-year mortality
following hospital discharge for HF were observed. Patients
experiencing AMI complicated by HF during recent study
years were increasingly older and more likely to have
significant comorbidities present than patients hospitalized
in the 1970s and 1980s; this may explain, in part, why the
long-term prognosis following HF has not improved over
time despite the more widespread application of more
effective treatment approaches. It is interesting that, even
after adjustment for age, gender and comorbidities, no
improvement in long-term outcome following HF was
discernible over the last 20 years. These findings highlight
the important prognostic influence of HF following AMI.
Lack of improvement over time in the long-term outlook of
these patients may also reflect the underutilization or
underdosing of effective cardiac therapies presently avail-
able, poor patient compliance or other features associated
with the natural history of HF.
This study was carried out in a well-defined metropolitan
area whose sociodemographic and economic characteristics
reflect those of the U.S. population as a whole with the
exception of race as the vast majority of Worcester SMSA
residents are white. Strengths of this study are the large
sample size, its population-based perspective enhancing the
generalizability of study findings and inclusion of all area-
wide hospitals. This study has several limitations: specific
therapy for patients with HF was not determined by a
standardized study protocol but by the many physicians
practicing at area-wide hospitals. In addition, given the
method of data collection and recording of hospital data, it
was difficult to determine whether a particular drug or
interventional procedure was used before or after the devel-
opment of HF. Due to our methods of data collection, we
were unable to determine changes in patients’ clinical status
following hospital discharge.
In summary, the results of this population-based study
suggest that, coincident with the increasingly aggressive
management of AMI, the incidence of HF has decreased
significantly in the last 20 years. Furthermore, while the
hospital prognosis associated with HF following AMI has
consistently improved over time, the one-year mortality rate
of hospital survivors of HF has not been favorably altered.
These findings reinforce the continued attention that needs
to be devoted to the early identification of patients at
increased risk for this syndrome and the application of
timely and effective preventive and treatment strategies. In
addition, it remains necessary to use the full complement of
effective secondary prevention approaches in patients devel-
oping left ventricular failure in the setting of AMI given
their impaired hospital and long-term prognosis compared
with patients not developing HF.
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